MetGlizer™-M1

10x15 Tablets

MetGlizer™-M1 is a combination of Metformin Hydrochloride (Prolonged Release) and Glimepiride, designed for the effective management of Type 2 Diabetes Mellitus (T2DM). This dual therapy helps in achieving better glycemic control by reducing hepatic glucose production (via Metformin) and enhancing insulin secretion from pancreatic β-cells (via Glimepiride). It is indicated as an adjunct to diet and exercise when monotherapy does not provide adequate control.

Common side effects may include:

• Hypoglycemia (low blood sugar)

• Nausea, vomiting, diarrhea, abdominal discomfort

• Headache, dizziness

• Weight gain (associated with Glimepiride)

• Metallic taste (rare, with Metformin)

Serious but rare side effects:

• Lactic Acidosis (with Metformin – a medical emergency)

• Severe hypoglycemia

• Hepatic dysfunction

• To be used under medical supervision.

• Recommended for Type 2 Diabetes Mellitus patients where diet, exercise, or monotherapy is insufficient.

• Administered orally with meals to reduce gastrointestinal side effects.

• Risk of hypoglycemia (especially in elderly, malnourished, or renal/hepatic impairment).

• Lactic acidosis risk with Metformin in renal impairment.

• May cause weight gain with long-term Glimepiride use.

• Not suitable for Type 1 Diabetes Mellitus or diabetic ketoacidosis.

• Type 1 Diabetes Mellitus or diabetic ketoacidosis.

• Renal impairment (eGFR < 30 mL/min/1.73 m²).

• Severe hepatic impairment.

• History of lactic acidosis.

• Pregnancy & lactation (unless advised by physician).

• Known hypersensitivity to Metformin, Glimepiride, or sulfonylureas.

• Monitor renal and hepatic function regularly.

• Avoid alcohol intake (increases risk of lactic acidosis & hypoglycemia).

• Use with caution in elderly patients.

• Monitor blood glucose levels regularly.

• Discontinue before surgical procedures or radiological studies involving contrast dye.

• As prescribed by the physician.

• Typically, one tablet once daily with meals (dosage may vary depending on patient’s response and tolerance).

• Do not crush or chew prolonged-release tablets.

• Increased hypoglycemia risk: With insulin, sulfonylureas, beta-blockers, ACE inhibitors, alcohol.

• Decreased efficacy: With corticosteroids, thiazide diuretics, oral contraceptives, thyroid products.

• Caution with contrast media: Temporary discontinuation of Metformin is required.

• Take medication with meals to minimize gastrointestinal side effects.

• Do not skip meals to avoid hypoglycemia.

• Follow prescribed dietary plan and exercise routine.

• Regularly monitor blood glucose and HbA1c.

• Carry glucose or sugar candy to manage unexpected hypoglycemia.

• Do not discontinue medication without consulting your physician.

• Storage: Store in a cool, dry place below 25°C. Protect from moisture and light.

• Shelf Life: As per packaging.

• American Diabetes Association (ADA) Standards of Medical Care in Diabetes – 2025.

• Indian Council of Medical Research (ICMR) Guidelines for Type 2 Diabetes Mellitus Management.

• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition.

• British National Formulary (BNF) – Antidiabetic Drugs.